This is a scientific update with no immediate financial or regulatory impact. Traders should watch for any subsequent regulatory or commercial developments, but this press release alone is unlikely to be a catalyst.
Drug in focus
AMRN drug pipeline →IPE
▼ Bearish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already on the market (approved 2012, expanded label 2019)
- Next catalyst
- None dated
What to watchWatch the Q3 2026 earnings release (~Oct 27–Nov 4) for updates on US market share erosion, net pricing trends, and international volume growth via Recordati. Key to watch: whether branded US market share can stabilize above 45% and whether operating expense cuts continue to offset top-line pressure. The EMT2 oncology results, while scientifically interesting, are not a near-term commercial catalyst and do not change the fundamental generic-overhang thesis.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 28 $13.97entry
- T+1 · 3mo ago −0.64%α −0.35% · $13.88
- T+5 · 2mo ago −2.43%α −2.54% · $13.63
- T+20 · 7w ago −5.15%α −5.41% · $13.25
- T+55 · todayOpen
- T+60 · in 6d Pending
Price Chart
How similar events traded
Executive Summary
Amarin announced a post-hoc analysis from the REDUCE-IT trial at ESC 2026, showing that highly adherent patients on icosapent ethyl (IPE) experienced ~30% relative risk reduction in MACE, and that benefits may persist for years after discontinuation (legacy effect). This is a scientific update on an already-approved drug, not a regulatory catalyst or new revenue driver, and does not change the company's commercial outlook or financial position.
Key Facts
- Post-hoc analysis of REDUCE-IT showed ~30% RRR in primary endpoint for high adherers on IPE for ≥1.5 years.
- Secondary prevention patients who stopped IPE after mean 2.3 years maintained HR of 0.73 for events occurring after discontinuation (legacy effect).
- The analysis is exploratory and presented at ESC 2026; no new regulatory or commercial catalyst.
- Amarin's market cap is ~$297M with 0% analyst bullishness and recent insider selling.
Financial Impact
No financial figures reported; the analysis does not change revenue, earnings, or guidance.
Risk Factors
- No new revenue or regulatory catalyst; the analysis is exploratory and does not change the commercial outlook.
- Historical underperformance on similar updates suggests limited positive price reaction.
- Low analyst bullishness (0%) and recent insider selling indicate weak sentiment.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352671 |
Track record
8 reports on AMRN
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 28, 202619d ago 8-K Neutral 5/10 No price data
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $12.75 Now $11.31 −11.26% settles Jan 26
- Oct 25, 202622d ago Press Release Mixed 6/10 Entry $12.09 Now $11.31 −6.45% settles Jan 22
- Aug 28, 202611w ago Press Release Neutral 4/10 Viewing Entry $13.97 Now $11.31 −19.04% settles Nov 23
- Jun 4, 202623w ago Court Ruling Bearish 7/10 Entry $13.80 to $13.97 Now $11.31 +18.04% ▼ −1.23% +0.65% vs SPY
- Apr 29, 202628w ago 8-K Neutral 4/10 Entry $14.29 to $13.55 Now $11.31 −20.85% ▼ −5.18% −9.29% vs SPY
- Mar 16, 202635w ago Press Release Neutral 4/10 Entry $15.42 to $14.20 Now $11.31 −26.65% ▼ −7.91% −18.40% vs SPY
- Feb 25, 202637w ago 8-K Bearish 6/10 Entry $14.05 to $14.27 Now $11.31 +19.50% ▼ −1.57% +5.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers